Physician profile
Mona M Castle
NPI 1437122751
$2,269.06
in general payments reported to CMS, 2019-2025
28 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $130 · 2021: $239 · 2022: $400 · 2023: $442 · 2024: $330 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $659.17 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $324.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $224.39 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $110.14 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Lilly USA, LLC | $103.43 | 2019-2025 | Jardiance, Zepbound, Emgality |
| Astellas Pharma US INC | $99.14 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $90.08 | 2020-2025 | |
| Daiichi Sankyo INC. | $70.04 | 2022 | |
| Amgen INC. | $55.04 | 2022-2025 | Evenity |
| Phathom Pharmaceuticals, INC. | $53.80 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $53.41 | 2023-2025 | Accrufer |
| Amarin Pharma, INC. | $47.43 | 2020 | |
| Nestle Healthcare Nutrition INC. | $38.18 | 2021-2022 | |
| Mylan Specialty L.P. | $37.81 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.93 | 2020-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.25 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $33.03 | 2019-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $26.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.28 | 2019-2021 | |
| Dexcom, INC. | $25.93 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.22 | 2021 | |
| Bausch Health US, LLC | $18.56 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.03 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.74 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.92 | 2024 | |
| Sunovion Pharmaceuticals INC. | $12.83 | 2019 | |
| Boston Scientific Corporation | $11.83 | 2019 | |
| Merck Sharp & Dohme LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Castle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.